| Pexidartinib studied in …STUDIED_INderived25 of 25show fewer |
|---|
| → studied in | NCT02390752Phase 1 · recruiting Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... · 25 trials list this drug (3 active) | — | — | Leukemia,Sarcoma,Acute Lymphoblastic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04488822Phase 3 · active not recruiting A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT · 25 trials list this drug (3 active) | — | — | Tenosynovial Giant Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04703322Phase 2 · completed A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan · 25 trials list this drug (3 active) | — | — | Tenosynovial Giant Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01042379Phase 2 · recruiting I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer · 25 trials list this drug (3 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Early Stage Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02975700NA · completed A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma · 25 trials list this drug (3 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02584647Phase 1/Phase 2 · terminated PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors · 25 trials list this drug (3 active) | — | — | Sarcoma,Malignant Peripheral Nerve Sheath Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02401815Phase 1/Phase 2 · completed CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors · 25 trials list this drug (3 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04526704Phase 4 · completed Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib · 25 trials list this drug (3 active) | — | — | Tenosynovial Giant Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02371369Phase 3 · completed Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) · 25 trials list this drug (3 active) | — | — | Tenosynovial Giant Cell Tumor,Tenosynovial Giant Cell Tumor, Diffuse Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02734433Phase 1 · completed Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors · 25 trials list this drug (3 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01004861Phase 1 · completed Safety Study of PLX108-01 in Patients With Solid Tumors · 25 trials list this drug (3 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02777710Phase 1 · completed Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers · 25 trials list this drug (3 active) | — | — | Malignant Neoplasm,Malignant Pancreatic Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02071940Phase 2 · completed PLX3397 KIT in Acral aNd mucOsal Melanoma · 25 trials list this drug (3 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04223635early Phase 1 · completed Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants · 25 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03291288Phase 1 · completed Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) · 25 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158103Phase 1 · completed A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) · 25 trials list this drug (3 active) | — | — | Gastrointestinal Stromal Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01596751Phase 1/Phase 2 · completed Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer · 25 trials list this drug (3 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01525602Phase 1 · completed Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors · 25 trials list this drug (3 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01217229Phase 2 · completed Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma · 25 trials list this drug (3 active) | — | — | Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01790503Phase 1/Phase 2 · completed A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma · 25 trials list this drug (3 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01826448Phase 1 · terminated A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma · 25 trials list this drug (3 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02452424Phase 1/Phase 2 · terminated A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors · 25 trials list this drug (3 active) | — | — | Melanoma,Gastrointestinal Stromal Tumor,Head and Neck Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01499043Phase 2 · terminated Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) · 25 trials list this drug (3 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01349036Phase 2 · terminated A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma · 25 trials list this drug (3 active) | — | — | Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01349049Phase 1/Phase 2 · completed Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML) · 25 trials list this drug (3 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |